Combined innate immune cell therapy, tumor-specific antibody, and radiation prompt antitumor response in pancreatic cancer models.

ABSTRACT: Pancreatic ductal adenocarcinoma (PDAC) is generally resistant to conventional immunotherapies due to its immunosuppressive tumor microenvironment (TME). We combine an innate cell-enriched product activated by interleukin-2 (IL-2) and zoledronic acid (ZA) (ICP^IL2ZA) with low-dose radiotherapy (RT) and monoclonal antibodies (mAbs) to overcome this immunosuppressive TME. ICP^IL2ZA is composed of natural killer (NK) cell- and monocyte-enriched immune cells, activated ex vivo with IL-2 and ZA. ICP^IL2ZA with RT and mAbs promotes antibody-dependent cellular cytotoxicity and phagocytosis against PDAC. In murine models of PDAC, RT and mAb combined with ICP^IL2ZA derived from either murine or healthy human donors controlled tumor growth. RT amplifies ICP

SUBMITTER: Rahman MM 

PROVIDER: S-EPMC12680064 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature